,51 Results of recent clinical trials in which anthracycline-based chemoimmunotherapy was combined with BCL-2 inhibitors further corroborate our findings: in fact, combinatory strategies based on the addition of venetoclax to R-CHOP produced suboptimal results in DLBCL, failing to provide a significant clinical benefit, as increased toxicities were not counterbalanced by increased effectiveness.27 The gene discussed is DDIT3; the disease is diffuse large B-cell lymphoma.